Here's where we are: President Trump paused pharma tariffs in their tracks after landing a massive deal with Pfizer.

Pfizer agreed to invest $70 billion in the U.S. over three years. In return? 

Tariff relief and a shot at reshaping how Americans pay for prescription drugs.

This isn't just another corporate handshake. It's a bet on bringing pharmaceutical jobs and research back to American soil.

Pfizer's putting serious money on the table.

The $70 billion will expand U.S. manufacturing and research facilities. The goal is making America less dependent on overseas drug production.

But get this: Pfizer also agreed to cut prices. Medicaid patients will see discounts between 50% and 85% on key medications. 

The company's adopting "Most Favored Nation" pricing, which means U.S. patients pay what other developed countries pay—not the inflated rates we're used to.

Pfizer CEO Albert Bourla says the deal gives his company the stability to invest bigger and faster. More jobs, more facilities, more drugs made here.

Other pharma companies are watching closely. 

Trump's team is already working on similar deals with other drugmakers. 

If you're running a major pharmaceutical company right now, you're feeling the pressure to match Pfizer's offer.

That pressure could mean more price cuts and more domestic investment across the board.

Healthcare stocks jumped on the news. Investors see opportunity, and three companies stand out for anyone looking to put money into this sector.

Eli Lilly is crushing it with diabetes and obesity treatments. Their pipeline looks strong, and the stock's at an attractive entry point for growth investors.

UnitedHealth Group just had a price dip, which analysts see as a buying opportunity. As the country's largest health insurer, they've got steady earnings and consistent execution.

Novo Nordisk leads the diabetes and obesity drug market with serious momentum. Their expansion plans and current valuation make them worth a look for long-term gains.

All three have solid fundamentals and analysts pointing to favorable entry points right now.

This deal could reshape American healthcare. 

Patients might finally catch a break on drug prices. Investors have clear opportunities in a sector that's getting a major shake-up. Pharma companies either play ball or risk getting left behind.

The three-year tariff pause gives Pfizer time to deliver on its promises. 

If it works, expect more companies to follow. If it doesn't, those tariffs could come roaring back.

Either way, the healthcare sector just got a lot more interesting. And for once, regular Americans might actually benefit from a Washington deal.

This analysis is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consider their individual circumstances before making investment decisions.